Loading stock data…
Artivion (AORT)
$25.28+0.28 (+1.12%)
Market ClosedLast close Jul 24
Artivion, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Artivion, Inc. in the Healthcare sector is trading at $25.28 with a market capitalization of $1.1B. Wall Street consensus targets $42.00 (8 analysts), implying a +66.1% move over the next 12 months. The stock is currently 48% below its 52-week high of $48.25, remaining 30.2% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +66.1% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $116.34M↑ | $115.99M↑ | $113.39M↑ | $112.97M↑ | $98.98M |
| Gross Profit | $75.45M↑ | $73.14M↓ | $74.39M↑ | $73.11M↑ | $63.58M |
| Operating Income | $5.79M↓ | $7.18M↓ | $9.04M↑ | $8.38M↑ | $2.15M |
| Net Income | $1.42M↓ | $2.43M↓ | $6.50M↑ | $1.34M↑ | -$505,000 |
Peer Comparison
JNJUNHPFE
Fundamentals
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; C...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.06B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
2.60%
Volume
Today's trading volume
246,486
Recent News
Below Expected Sales for AMDS Hurt Artivion (AORT) in Q2
Fred Alger Management, an investment management company, released its “Alger Weatherbie Specialized Growth Fund” second-quarter 2026 investor letter. A copy of the letter can be downloaded here. U.S. equities experienced a strong recovery in Q2 2026, with the S&P 500 Index gaining 15.2%, marking its best quarter since 2020. A ceasefire between the United States […]
Intuitive Surgical, Inc. (ISRG) Q2 Earnings and Revenues Top Estimates
Intuitive Surgical (ISRG) delivered earnings and revenue surprises of +12.90% and +3.08%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
3 Reasons to Sell AORT and 1 Stock to Buy Instead
Artivion’s stock price has taken a beating over the past six months, shedding 43.8% of its value and falling to $24.10 per share. This was partly due to its softer quarterly results and might have investors contemplating their next move.
3 Stocks Under $50 with Warning Signs
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.
2 Growth Stocks Set to Flourishand 1 We Ignore
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who lost money in tech stocks during 2022.